Is It Time To Consider Buying Danaher Corporation (NYSE:DHR)?
Let's talk about the popular Danaher Corporation ( NYSE:DHR ). The company's shares received a lot of attention from a...
Has the U.S. Clinical Research and Equipment Industry valuation changed over the past few years?
|Sun, 29 May 2022||US$773.5b||US$148.1b||US$20.1b||31.8x|
|Tue, 26 Apr 2022||US$804.5b||US$147.3b||US$25.4b||31.8x|
|Thu, 24 Mar 2022||US$846.7b||US$145.0b||US$25.3b||35.2x|
|Sat, 19 Feb 2022||US$825.6b||US$144.8b||US$25.4b||37.9x|
|Mon, 17 Jan 2022||US$878.1b||US$138.0b||US$27.3b||39.9x|
|Wed, 15 Dec 2021||US$960.7b||US$138.0b||US$27.3b||43.2x|
|Fri, 12 Nov 2021||US$963.1b||US$137.8b||US$27.1b||46.1x|
|Sun, 10 Oct 2021||US$709.1b||US$105.9b||US$18.6b||46x|
|Tue, 07 Sep 2021||US$754.5b||US$106.0b||US$18.6b||51.2x|
|Thu, 05 Aug 2021||US$718.4b||US$105.8b||US$18.7b||47.8x|
|Sun, 09 May 2021||US$604.0b||US$97.3b||US$17.5b||41.2x|
|Wed, 10 Feb 2021||US$596.2b||US$89.8b||US$14.6b||44.4x|
|Tue, 03 Nov 2020||US$465.9b||US$80.2b||US$11.9b||38.8x|
|Fri, 07 Aug 2020||US$440.2b||US$77.2b||US$8.9b||42.4x|
|Thu, 30 Apr 2020||US$355.0b||US$77.3b||US$8.5b||34.3x|
|Sun, 02 Feb 2020||US$349.5b||US$76.8b||US$8.6b||34x|
|Wed, 06 Nov 2019||US$324.1b||US$75.6b||US$7.0b||33.3x|
|Sat, 10 Aug 2019||US$334.7b||US$76.6b||US$8.3b||36.2x|
How does U.S. Clinical Research and Equipment compare with similar industries?
|Clinical Research and Equipment||5.09%|
Which companies have driven the market over the last 7 days?
Thermo Fisher Scientific
Inotiv has largely focused on pre-clinical services that is performed prior to the initiation of any clinical trials in humans. NOTV’s revenue declined by 38% from 2011-2016 and EBITDA turned negative in 2016. Revenue has grown significantly from $20mm in FY ’16 to a projected $460mm in FY’22 ($180mm excluding Envigo). NOTV could also be an attractive M&A candidate for any of the larger CRO’s who are looking to increase their exposure to both biotech customers as well as preclinical services. As investors gain more visibility into both the run-rate revenue and earnings potential of NOTV, the stock should benefit from multiple expansion in-line with other CRO peers.
Singular Genomics Systems
West Pharmaceutical Services
Applied DNA Sciences
IQVIA has the potential to outperform the market in a higher inflation environment. Significant growth potential with projected 17.72% FCF and 11.68% EBIT CAGR over the next 5 years. Decentralized clinical trials, the emergence of virtual trials, blockchain technologies, AI and ML applications are great future growth drivers. Based on my valuation model, the stock has most likely a 28% upside potential with a price target at $282.